Related Experiment Video
Updated: Jul 11, 2026

08:49
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
45.3K
Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer
Nicolas Berger1, Benjamin Kugler1, Dong Han
1Department of Exercise and Health Sciences, Manning College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA.
Medicine and Science in Sports and Exercise
|April 2, 2025
Summary
Voluntary wheel running reduced tumor growth in a mouse model of Castration-Resistant Prostate Cancer (CRPC). This exercise delayed tumor progression by downregulating DNA replication, Androgen Receptor (AR) signaling, and angiogenesis pathways.
Area of Science:
- Oncology
- Exercise Physiology
- Molecular Biology
Background:
- Prostate cancer progression, particularly Castration-Resistant Prostate Cancer (CRPC), remains a significant clinical challenge.
- Understanding the molecular mechanisms underlying tumor growth is crucial for developing novel therapeutic strategies.
- The role of physical activity in cancer management is an emerging area of research.
Purpose of the Study:
- To investigate the impact of voluntary wheel running (VWR) on tumor growth in a CRPC mouse model.
- To explore the potential molecular pathways, including DNA replication, Androgen Receptor (AR) signaling, and mitochondrial dynamics, affected by VWR.
Main Methods:
- A CRPC xenograft mouse model was established using human CWR-22RV1 cells.
- Mice were divided into voluntary wheel running (VWR) and sedentary (SED) groups.
- Tumor volume was monitored, and tumor tissues were analyzed for gene and protein expression using RT-PCR, western blotting, and transcriptomics.
Main Results:
- VWR significantly reduced tumor volume and attenuated tumor progression compared to the SED group.
- Reduced tumor growth correlated with lower mRNA expression of DNA replication markers (MCM2, MCM6, MCM7) and AR signaling targets (ELOVL5, FKBP5).
- VWR also altered mitochondrial dynamics markers and downregulated pathways involved in angiogenesis and extracellular matrix formation.
Conclusions:
- Three weeks of VWR effectively delayed tumor formation and progression in this CRPC model.
- The observed benefits are associated with reduced transcription of DNA replication, AR signaling, and mitochondrial dynamics.
- Downregulation of angiogenesis pathways may contribute to the anti-tumor effects of VWR.
More Related Videos
Related Concept Videos
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

